297 related articles for article (PubMed ID: 8112038)
1. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Aldridge KE
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
3. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
4. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1990 Aug; 34(8):1546-50. PubMed ID: 2221864
[TBL] [Abstract][Full Text] [Related]
5. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
Aldridge KE; Henderberg A; Sanders CV
J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
[TBL] [Abstract][Full Text] [Related]
6. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
Jacobs MR; Spangler SK; Appelbaum PC
J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
[TBL] [Abstract][Full Text] [Related]
7. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
8. beta-Lactamase production and susceptibility of US and European anaerobic gram-negative bacilli to beta-lactams and other agents.
Jacobs MR; Spangler SK; Appelbaum PC
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1081-93. PubMed ID: 1295763
[TBL] [Abstract][Full Text] [Related]
9. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
[TBL] [Abstract][Full Text] [Related]
10. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
[TBL] [Abstract][Full Text] [Related]
11. Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.
Snydman DR; Jacobus NV; McDermott LA; Goldstein EJ; Harrell L; Jenkins SG; Newton D; Patel R; Hecht DW
Anaerobe; 2017 Feb; 43():21-26. PubMed ID: 27867083
[TBL] [Abstract][Full Text] [Related]
12. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Bacteroides non-fragilis and fusobacteria to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole.
Jacobs MR; Spangler SK; Appelbaum PC
Eur J Clin Microbiol Infect Dis; 1990 Jun; 9(6):417-21. PubMed ID: 2387295
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
[TBL] [Abstract][Full Text] [Related]
15. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
Lachance N; Gaudreau C; Lamothe F; Turgeon F
Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
[TBL] [Abstract][Full Text] [Related]
16. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
Betriu C; Cabronero C; Gomez M; Picazo JJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
[TBL] [Abstract][Full Text] [Related]
17. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
Wüst J; Hardegger U
Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
[TBL] [Abstract][Full Text] [Related]
19. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of YTR 830.
Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S
J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
